NCT07465900

Brief Summary

This prospective interventional study evaluates the effectiveness of Cylindrical Annular Refractive Element (C.A.R.E.) spectacle lenses in slowing axial elongation and myopia progression in children aged 6-12 years. A total of 100 participants with myopia ranging from -0.75 to -6.00 diopters were enrolled and prescribed C.A.R.E. spectacle lenses for full-time wear over a 12-month period. Clinical examinations are conducted at baseline, 6 months, and 12 months and include measurements of axial length, cycloplegic refraction, and visual acuity. The primary outcome measure is the change in axial length over the 12-month study period. Secondary outcomes include changes in spherical equivalent refractive error, visual acuity, and safety outcomes related to spectacle lens wear.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
100

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Jan 2024

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 15, 2024

Completed
1.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 15, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 15, 2025

Completed
12 months until next milestone

First Submitted

Initial submission to the registry

March 6, 2026

Completed
6 days until next milestone

First Posted

Study publicly available on registry

March 12, 2026

Completed
Last Updated

March 12, 2026

Status Verified

March 1, 2026

Enrollment Period

1.2 years

First QC Date

March 6, 2026

Last Update Submit

March 10, 2026

Conditions

Keywords

Myopia ControlC.A.R.E. LensesAxial ElongationPediatric Ophthalmology

Outcome Measures

Primary Outcomes (1)

  • Change in Axial Length

    Axial length (AL) will be measured using non-contact optical biometry at baseline, 6 months, and 12 months. The primary outcome is the difference in axial length from baseline to 12 months to evaluate the effect of C.A.R.E. lenses on slowing ocular elongation in children with myopia.

    Baseline to 12 months

Secondary Outcomes (1)

  • Change in Spherical Equivalent Refractive Error (SER)

    Baseline to 12 months

Study Arms (1)

C.A.R.E. Spectacle Lenses - Pediatric Myopia Control

EXPERIMENTAL

All participants received Cylindrical Annular Refractive Element (C.A.R.E.) spectacle lenses. The lenses feature a central optical zone for distance correction surrounded by concentric annular cylindrical elements designed to modify peripheral retinal defocus and slow axial elongation. Participants were instructed to wear the spectacles full-time during waking hours for 12 months. Follow-up examinations occurred at baseline, 6 months, and 12 months to assess axial length, refractive error, visual acuity, and safety.

Device: Cylindrical Annular Refractive Element (C.A.R.E.) Spectacle Lenses

Interventions

C.A.R.E. spectacle lenses feature a central optical zone for distance correction surrounded by concentric annular cylindrical elements that modify peripheral retinal defocus to slow axial elongation in children with myopia. Participants were instructed to wear the lenses full-time during waking hours for 12 months. Follow-up assessments were conducted at baseline, 6 months, and 12 months, measuring axial length, refractive error, visual acuity, and safety.

Also known as: C.A.R.E. lenses
C.A.R.E. Spectacle Lenses - Pediatric Myopia Control

Eligibility Criteria

Age6 Years - 12 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)

You may qualify if:

  • Children aged 6-12 years at enrollment.
  • Spherical equivalent refractive error between -0.75 and -6.00 diopters.
  • Astigmatism ≤1.50 diopters.
  • Best-corrected visual acuity of 0.1 logMAR or better.
  • Ability to comply with full-time spectacle wear.
  • Informed consent obtained from parent or legal guardian.

You may not qualify if:

  • Amblyopia or strabismus.
  • Keratoconus or other corneal pathology.
  • Previous myopia control treatment (e.g., atropine therapy, orthokeratology).
  • History of ocular surgery.
  • Systemic disease affecting vision.
  • Poor compliance with spectacle wear.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Benha University

Banhā, Benha, 13111, Egypt

Location

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Masking Details
Not applicable; participants, investigators, and outcome assessors were aware of the intervention.
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Model Details: All participants received C.A.R.E. spectacle lenses for full-time daily wear over 12 months. No control group was included in this single-arm study.
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Lecturer of Ophthalmology

Study Record Dates

First Submitted

March 6, 2026

First Posted

March 12, 2026

Study Start

January 15, 2024

Primary Completion

March 15, 2025

Study Completion

March 15, 2025

Last Updated

March 12, 2026

Record last verified: 2026-03

Locations